Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma
Purpose: To correlate the immunohistochemical expression of topoisomerase IIα (topoIIα) in Hodgkin's lymphoma (HL) with clinicopathological parameters, the expression of Ki-67 and the outcome of patients, who had been homogenously treated with ABVD or equivalent regimens. Experimental Design: I...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2008-03, Vol.14 (6), p.1759-1766 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1766 |
|---|---|
| container_issue | 6 |
| container_start_page | 1759 |
| container_title | Clinical cancer research |
| container_volume | 14 |
| creator | DOUSSIS-ANAGNOSTOPOULOU, Ipatia A VASSILAKOPOULOS, Theodoros P KAKLAMANIS, Loukas PANAYIOTIDIS, Panayiotis KYRTSONIS, Marie-Christine ANDROULAKI, Athina PATSOURIS, Efstratios KITTAS, Christos PANGALIS, Gerassimos A THYMARA, Irini KORKOLOPOULOU, Penelope ANGELOPOULOU, Maria K SIAKANTARIS, Marina P KOKORIS, Styliani I DIMITRIADOU, Evangelia M KALPADAKIS, Christina MATZOURANIS, Marina |
| description | Purpose: To correlate the immunohistochemical expression of topoisomerase IIα (topoIIα) in Hodgkin's lymphoma (HL) with clinicopathological
parameters, the expression of Ki-67 and the outcome of patients, who had been homogenously treated with ABVD or equivalent
regimens.
Experimental Design: Immunohistochemistry using the monoclonal antibody Ki-S1 (topoIIα) was performed in 238 HL patients. MiB1 (Ki-67) expression
was evaluated in 211/238.
Results: The mean ± SD percentage of topoIIα- and Ki-67–positive Hodgkin-Reed-Sternberg (HRS) cells was 63 ± 19% (5%-98%) and 73 ±
19% (8%-99%), respectively. The median percentage of topoIIα-positive HRS cells was 64% (interquartile range, 51-78%). There
was no correlation between topoIIα expression and patient characteristics. TopoIIα and Ki-67 expression were correlated (Spearman's
Rho 0.255, P < 0.001). TopoIlα expression within the highest quartile of this patient population was predictive of failure free survival
(FFS) (10-year rates 82 ± 3% vs 68 ± 7%, P = 0.02 for patients falling into the quartiles 1-3 and 4 respectively). In multivariate analysis topoIIα expression was independently
predictive of FFS.
Conclusion: TopoIIα was expressed in all cases of HL showing a correlation with Ki-67 expression. Under current standard therapy including
drugs inhibiting its activity, topoIIα was an independent adverse predictor of FFS with no statistically significant correlation
with other established prognostic factors. |
| doi_str_mv | 10.1158/1078-0432.CCR-07-1395 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20002917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20002917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-37e25fdca96096efc7d7ec4abeb34291297786c6661b7dda8d7a4eac58174663</originalsourceid><addsrcrecordid>eNo9kEtuFDEQhi0EIg84ApI3QDYd7G4_updolMdIIxFFI7G0atzVM4Zpu3F1lORYXIQz4dEENlW1-Krq18fYBykupdTtFylsWwnV1JeLxX0lbCWbTr9ip1JrWzW10a_L_I85YWdEP4SQSgr1lp3ItlFWWnvKvq_TlAKlETMQ8uXyz29-9TRlJAopciAOkS9jjxOWEmd-l9M2JpqD59fg55R5iPw29dufIX4mvnoep10a4R17M8Ce8P1LP2fr66v14rZafbtZLr6uKl8SzFVjsdZD76EzojM4eNtb9Ao2uGlU3cm6s7Y13hgjN7bvoe0tKASvW2mVMc05-3Q8O-X06wFpdmMgj_s9REwP5GohRDljC6iPoM-JKOPgphxGyM9OCncQ6g6y3EGWK0KdsO4gtOx9fHkA5GE_ZIg-0P_lWtRKlpiFuzhyu7DdPYaMzhcScxGJkP3OSeWMk1Z3zV-L54OE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20002917</pqid></control><display><type>article</type><title>Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><source>Alma/SFX Local Collection</source><creator>DOUSSIS-ANAGNOSTOPOULOU, Ipatia A ; VASSILAKOPOULOS, Theodoros P ; KAKLAMANIS, Loukas ; PANAYIOTIDIS, Panayiotis ; KYRTSONIS, Marie-Christine ; ANDROULAKI, Athina ; PATSOURIS, Efstratios ; KITTAS, Christos ; PANGALIS, Gerassimos A ; THYMARA, Irini ; KORKOLOPOULOU, Penelope ; ANGELOPOULOU, Maria K ; SIAKANTARIS, Marina P ; KOKORIS, Styliani I ; DIMITRIADOU, Evangelia M ; KALPADAKIS, Christina ; MATZOURANIS, Marina</creator><creatorcontrib>DOUSSIS-ANAGNOSTOPOULOU, Ipatia A ; VASSILAKOPOULOS, Theodoros P ; KAKLAMANIS, Loukas ; PANAYIOTIDIS, Panayiotis ; KYRTSONIS, Marie-Christine ; ANDROULAKI, Athina ; PATSOURIS, Efstratios ; KITTAS, Christos ; PANGALIS, Gerassimos A ; THYMARA, Irini ; KORKOLOPOULOU, Penelope ; ANGELOPOULOU, Maria K ; SIAKANTARIS, Marina P ; KOKORIS, Styliani I ; DIMITRIADOU, Evangelia M ; KALPADAKIS, Christina ; MATZOURANIS, Marina</creatorcontrib><description>Purpose: To correlate the immunohistochemical expression of topoisomerase IIα (topoIIα) in Hodgkin's lymphoma (HL) with clinicopathological
parameters, the expression of Ki-67 and the outcome of patients, who had been homogenously treated with ABVD or equivalent
regimens.
Experimental Design: Immunohistochemistry using the monoclonal antibody Ki-S1 (topoIIα) was performed in 238 HL patients. MiB1 (Ki-67) expression
was evaluated in 211/238.
Results: The mean ± SD percentage of topoIIα- and Ki-67–positive Hodgkin-Reed-Sternberg (HRS) cells was 63 ± 19% (5%-98%) and 73 ±
19% (8%-99%), respectively. The median percentage of topoIIα-positive HRS cells was 64% (interquartile range, 51-78%). There
was no correlation between topoIIα expression and patient characteristics. TopoIIα and Ki-67 expression were correlated (Spearman's
Rho 0.255, P < 0.001). TopoIlα expression within the highest quartile of this patient population was predictive of failure free survival
(FFS) (10-year rates 82 ± 3% vs 68 ± 7%, P = 0.02 for patients falling into the quartiles 1-3 and 4 respectively). In multivariate analysis topoIIα expression was independently
predictive of FFS.
Conclusion: TopoIIα was expressed in all cases of HL showing a correlation with Ki-67 expression. Under current standard therapy including
drugs inhibiting its activity, topoIIα was an independent adverse predictor of FFS with no statistically significant correlation
with other established prognostic factors.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-07-1395</identifier><identifier>PMID: 18347177</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; doxorubicine ; etoposide ; Hematologic and hematopoietic diseases ; Hodgkin's lymphoma ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Pharmacology. Drug treatments ; prognostic factors ; topoisomerase IIα</subject><ispartof>Clinical cancer research, 2008-03, Vol.14 (6), p.1759-1766</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-37e25fdca96096efc7d7ec4abeb34291297786c6661b7dda8d7a4eac58174663</citedby><cites>FETCH-LOGICAL-c347t-37e25fdca96096efc7d7ec4abeb34291297786c6661b7dda8d7a4eac58174663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3343,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20241912$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>DOUSSIS-ANAGNOSTOPOULOU, Ipatia A</creatorcontrib><creatorcontrib>VASSILAKOPOULOS, Theodoros P</creatorcontrib><creatorcontrib>KAKLAMANIS, Loukas</creatorcontrib><creatorcontrib>PANAYIOTIDIS, Panayiotis</creatorcontrib><creatorcontrib>KYRTSONIS, Marie-Christine</creatorcontrib><creatorcontrib>ANDROULAKI, Athina</creatorcontrib><creatorcontrib>PATSOURIS, Efstratios</creatorcontrib><creatorcontrib>KITTAS, Christos</creatorcontrib><creatorcontrib>PANGALIS, Gerassimos A</creatorcontrib><creatorcontrib>THYMARA, Irini</creatorcontrib><creatorcontrib>KORKOLOPOULOU, Penelope</creatorcontrib><creatorcontrib>ANGELOPOULOU, Maria K</creatorcontrib><creatorcontrib>SIAKANTARIS, Marina P</creatorcontrib><creatorcontrib>KOKORIS, Styliani I</creatorcontrib><creatorcontrib>DIMITRIADOU, Evangelia M</creatorcontrib><creatorcontrib>KALPADAKIS, Christina</creatorcontrib><creatorcontrib>MATZOURANIS, Marina</creatorcontrib><title>Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma</title><title>Clinical cancer research</title><description>Purpose: To correlate the immunohistochemical expression of topoisomerase IIα (topoIIα) in Hodgkin's lymphoma (HL) with clinicopathological
parameters, the expression of Ki-67 and the outcome of patients, who had been homogenously treated with ABVD or equivalent
regimens.
Experimental Design: Immunohistochemistry using the monoclonal antibody Ki-S1 (topoIIα) was performed in 238 HL patients. MiB1 (Ki-67) expression
was evaluated in 211/238.
Results: The mean ± SD percentage of topoIIα- and Ki-67–positive Hodgkin-Reed-Sternberg (HRS) cells was 63 ± 19% (5%-98%) and 73 ±
19% (8%-99%), respectively. The median percentage of topoIIα-positive HRS cells was 64% (interquartile range, 51-78%). There
was no correlation between topoIIα expression and patient characteristics. TopoIIα and Ki-67 expression were correlated (Spearman's
Rho 0.255, P < 0.001). TopoIlα expression within the highest quartile of this patient population was predictive of failure free survival
(FFS) (10-year rates 82 ± 3% vs 68 ± 7%, P = 0.02 for patients falling into the quartiles 1-3 and 4 respectively). In multivariate analysis topoIIα expression was independently
predictive of FFS.
Conclusion: TopoIIα was expressed in all cases of HL showing a correlation with Ki-67 expression. Under current standard therapy including
drugs inhibiting its activity, topoIIα was an independent adverse predictor of FFS with no statistically significant correlation
with other established prognostic factors.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>doxorubicine</subject><subject>etoposide</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hodgkin's lymphoma</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>prognostic factors</subject><subject>topoisomerase IIα</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNo9kEtuFDEQhi0EIg84ApI3QDYd7G4_updolMdIIxFFI7G0atzVM4Zpu3F1lORYXIQz4dEENlW1-Krq18fYBykupdTtFylsWwnV1JeLxX0lbCWbTr9ip1JrWzW10a_L_I85YWdEP4SQSgr1lp3ItlFWWnvKvq_TlAKlETMQ8uXyz29-9TRlJAopciAOkS9jjxOWEmd-l9M2JpqD59fg55R5iPw29dufIX4mvnoep10a4R17M8Ce8P1LP2fr66v14rZafbtZLr6uKl8SzFVjsdZD76EzojM4eNtb9Ao2uGlU3cm6s7Y13hgjN7bvoe0tKASvW2mVMc05-3Q8O-X06wFpdmMgj_s9REwP5GohRDljC6iPoM-JKOPgphxGyM9OCncQ6g6y3EGWK0KdsO4gtOx9fHkA5GE_ZIg-0P_lWtRKlpiFuzhyu7DdPYaMzhcScxGJkP3OSeWMk1Z3zV-L54OE</recordid><startdate>20080315</startdate><enddate>20080315</enddate><creator>DOUSSIS-ANAGNOSTOPOULOU, Ipatia A</creator><creator>VASSILAKOPOULOS, Theodoros P</creator><creator>KAKLAMANIS, Loukas</creator><creator>PANAYIOTIDIS, Panayiotis</creator><creator>KYRTSONIS, Marie-Christine</creator><creator>ANDROULAKI, Athina</creator><creator>PATSOURIS, Efstratios</creator><creator>KITTAS, Christos</creator><creator>PANGALIS, Gerassimos A</creator><creator>THYMARA, Irini</creator><creator>KORKOLOPOULOU, Penelope</creator><creator>ANGELOPOULOU, Maria K</creator><creator>SIAKANTARIS, Marina P</creator><creator>KOKORIS, Styliani I</creator><creator>DIMITRIADOU, Evangelia M</creator><creator>KALPADAKIS, Christina</creator><creator>MATZOURANIS, Marina</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope></search><sort><creationdate>20080315</creationdate><title>Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma</title><author>DOUSSIS-ANAGNOSTOPOULOU, Ipatia A ; VASSILAKOPOULOS, Theodoros P ; KAKLAMANIS, Loukas ; PANAYIOTIDIS, Panayiotis ; KYRTSONIS, Marie-Christine ; ANDROULAKI, Athina ; PATSOURIS, Efstratios ; KITTAS, Christos ; PANGALIS, Gerassimos A ; THYMARA, Irini ; KORKOLOPOULOU, Penelope ; ANGELOPOULOU, Maria K ; SIAKANTARIS, Marina P ; KOKORIS, Styliani I ; DIMITRIADOU, Evangelia M ; KALPADAKIS, Christina ; MATZOURANIS, Marina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-37e25fdca96096efc7d7ec4abeb34291297786c6661b7dda8d7a4eac58174663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>doxorubicine</topic><topic>etoposide</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hodgkin's lymphoma</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>prognostic factors</topic><topic>topoisomerase IIα</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DOUSSIS-ANAGNOSTOPOULOU, Ipatia A</creatorcontrib><creatorcontrib>VASSILAKOPOULOS, Theodoros P</creatorcontrib><creatorcontrib>KAKLAMANIS, Loukas</creatorcontrib><creatorcontrib>PANAYIOTIDIS, Panayiotis</creatorcontrib><creatorcontrib>KYRTSONIS, Marie-Christine</creatorcontrib><creatorcontrib>ANDROULAKI, Athina</creatorcontrib><creatorcontrib>PATSOURIS, Efstratios</creatorcontrib><creatorcontrib>KITTAS, Christos</creatorcontrib><creatorcontrib>PANGALIS, Gerassimos A</creatorcontrib><creatorcontrib>THYMARA, Irini</creatorcontrib><creatorcontrib>KORKOLOPOULOU, Penelope</creatorcontrib><creatorcontrib>ANGELOPOULOU, Maria K</creatorcontrib><creatorcontrib>SIAKANTARIS, Marina P</creatorcontrib><creatorcontrib>KOKORIS, Styliani I</creatorcontrib><creatorcontrib>DIMITRIADOU, Evangelia M</creatorcontrib><creatorcontrib>KALPADAKIS, Christina</creatorcontrib><creatorcontrib>MATZOURANIS, Marina</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DOUSSIS-ANAGNOSTOPOULOU, Ipatia A</au><au>VASSILAKOPOULOS, Theodoros P</au><au>KAKLAMANIS, Loukas</au><au>PANAYIOTIDIS, Panayiotis</au><au>KYRTSONIS, Marie-Christine</au><au>ANDROULAKI, Athina</au><au>PATSOURIS, Efstratios</au><au>KITTAS, Christos</au><au>PANGALIS, Gerassimos A</au><au>THYMARA, Irini</au><au>KORKOLOPOULOU, Penelope</au><au>ANGELOPOULOU, Maria K</au><au>SIAKANTARIS, Marina P</au><au>KOKORIS, Styliani I</au><au>DIMITRIADOU, Evangelia M</au><au>KALPADAKIS, Christina</au><au>MATZOURANIS, Marina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma</atitle><jtitle>Clinical cancer research</jtitle><date>2008-03-15</date><risdate>2008</risdate><volume>14</volume><issue>6</issue><spage>1759</spage><epage>1766</epage><pages>1759-1766</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: To correlate the immunohistochemical expression of topoisomerase IIα (topoIIα) in Hodgkin's lymphoma (HL) with clinicopathological
parameters, the expression of Ki-67 and the outcome of patients, who had been homogenously treated with ABVD or equivalent
regimens.
Experimental Design: Immunohistochemistry using the monoclonal antibody Ki-S1 (topoIIα) was performed in 238 HL patients. MiB1 (Ki-67) expression
was evaluated in 211/238.
Results: The mean ± SD percentage of topoIIα- and Ki-67–positive Hodgkin-Reed-Sternberg (HRS) cells was 63 ± 19% (5%-98%) and 73 ±
19% (8%-99%), respectively. The median percentage of topoIIα-positive HRS cells was 64% (interquartile range, 51-78%). There
was no correlation between topoIIα expression and patient characteristics. TopoIIα and Ki-67 expression were correlated (Spearman's
Rho 0.255, P < 0.001). TopoIlα expression within the highest quartile of this patient population was predictive of failure free survival
(FFS) (10-year rates 82 ± 3% vs 68 ± 7%, P = 0.02 for patients falling into the quartiles 1-3 and 4 respectively). In multivariate analysis topoIIα expression was independently
predictive of FFS.
Conclusion: TopoIIα was expressed in all cases of HL showing a correlation with Ki-67 expression. Under current standard therapy including
drugs inhibiting its activity, topoIIα was an independent adverse predictor of FFS with no statistically significant correlation
with other established prognostic factors.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>18347177</pmid><doi>10.1158/1078-0432.CCR-07-1395</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2008-03, Vol.14 (6), p.1759-1766 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20002917 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Biological and medical sciences doxorubicine etoposide Hematologic and hematopoietic diseases Hodgkin's lymphoma Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Pharmacology. Drug treatments prognostic factors topoisomerase IIα |
| title | Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A14%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Topoisomerase%20II%CE%B1%20Expression%20as%20an%20Independent%20Prognostic%20Factor%20in%20Hodgkin's%20Lymphoma&rft.jtitle=Clinical%20cancer%20research&rft.au=DOUSSIS-ANAGNOSTOPOULOU,%20Ipatia%20A&rft.date=2008-03-15&rft.volume=14&rft.issue=6&rft.spage=1759&rft.epage=1766&rft.pages=1759-1766&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-07-1395&rft_dat=%3Cproquest_cross%3E20002917%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20002917&rft_id=info:pmid/18347177&rfr_iscdi=true |